(AOF) – SpineGuard announces the implementation of a bond financing for a potential maximum nominal amount of 7.5 million euros with Nice & Green SA, an investment company of which it has been a partner since 2017. Guidance specialist real-time surgery (DSG) to secure and simplify the placement of bone implants, Spineguard specifies that it is a question for it “in a volatile macro-economic context”, of securing its long-term financing, by capitalizing on its “good performance” in 2022 and 2023.
The company plans to use this financing, dubbed the “Horizon Program” to notably “accelerate the commercial, marketing and logistics reinforcement” of its subsidiary in the United States in order to support its growth in its main market. It will also have to “repay its bond debt in advance” in order to improve its balance sheet and reduce its financial costs and “constitute an envelope of financing that can be mobilized for opportunities for growth and innovation”.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.